Nifty 50 staged a sharp rebound on Friday, June 12, reclaiming the 23,500 zone after defending crucial support near 23,000, setting up a watchful start to Monday’s session. A cluster of single-stock triggers, a US pharma launch, a record-scale battery storage milestone, a thermal power acquisition, a hospital chain’s fundraise, and an FMCG controversy will keep Dr Reddy’s, Adani Green Energy, JSW Energy, KIMS, and Nestlé India in sharp focus today.
Key Takeaways
- Nifty 50 closed at 23,631.75, up 470.15 points or 2.03 percent, while the Sensex closed at 75,532.94, up 1,700.39 points or 2.30 percent on Friday, June 12.
- Dr Reddy’s launched a generic version of Bosulif (Bosutinib 400mg) in the US with 180-day exclusivity; the branded drug recorded sales of approximately $253.8 million for the 12-month period ended April 2026 in the US.
- Adani Green Energy commissioned a cumulative 3.37 GWh Battery Energy Storage System at Khavda, Gujarat, the world’s largest single-location BESS deployment outside China.
- JSW Energy signed a definitive pact to acquire 100% equity of Maruti Clean Coal & Power Limited, which operates a 300 MW thermal plant in Chhattisgarh, for an enterprise value of approximately ₹1,410 crore.
- KIMS’ board approved issuing 77.02 lakh warrants priced at ₹779 each to promoters, raising about ₹600 crore, convertible within 18 months.
- Nestlé India rejected infestation allegations in Maggi noodles after FSSAI sought a clarification, saying lab tests on batch and market samples met quality and food safety standards; the stock had closed 3.29 percent lower at Rs 1,375.70 on Friday.
Market Setup: Nifty Defends 23,000, Eyes 23,800–24,200
Friday’s session marked a decisive turnaround for Indian equities.
According to closing data, the Nifty 50 settled at 23,631.75, up 470.15 points, or 2.03 percent; the Sensex closed at 75,532.94, up 1,700.39 points, or 2.30 percent; and the Bank Nifty ended at 56,805.50, up 1,628.75 points, or 2.95 percent. Volatility cooled sharply too, with India VIX dropping 5.7 percent to 14.72 from 15.61.
Sector-wise, banks, NBFCs, capital goods, and telecom led the charge, with Bajaj Finance up 5.49 percent, Larsen & Toubro up 4.85 percent, and HDFC Bank up 3.74 percent, while IT and metals lagged. Easing crude prices on hopes of a US-Iran de-escalation also supported sentiment, per reports of the Sensex surging 1,695 points and Nifty topping 23,600 as oil tumbled on US-Iran peace hopes.
On the institutional flows front, the picture remains mixed. FIIs sold Rs 2,249.03 crore while DIIs bought Rs 4,365.11 crore on June 11, with Friday’s provisional figures awaited.
Separately, NSE data shows FII outflows of ₹1,082.18 crore against DII inflows of ₹5,341.29 crore for June 12, underlining the now-familiar pattern of domestic institutions cushioning foreign selling.
Nifty 50: Key Technical Levels for Today
| Level Type | Range/Value |
|---|---|
| Friday’s Close | 23,631.75 |
| Day’s Range (June 12) | 23,313.90 – 23,645.35 |
| Immediate Resistance | 23,700 – 23,800 |
| Upside Target Zone | 23,800 – 24,200 |
| Immediate Support | 23,400 – 23,300 |
| Deeper Support | 23,100 – 23,000 |
| India VIX | 14.72 (down from 15.61) |
Sources: ICICI Direct, Univest Market Outlook
For traders watching positioning ahead of the open, NiftyTrader’s Option Chain Analysis tool and FII-DII Activity tracker can help gauge whether Friday’s momentum carries through or fades into profit-booking near resistance.
Dr Reddy’s: First-to-Market Bosutinib Launch in the US
Dr Reddy’s Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States on June 13. The company collaborated with MSN Laboratories Private Limited on this product, holding exclusive marketing rights in the US while MSN handles development and manufacturing.
Significantly, Bosutinib Tablets 400 mg was a first-to-file product and is eligible for 180 days of generic drug exclusivity for this strength in the US, a meaningful head-start over rival generic players.
Bosulif, sold by Pfizer, is used to treat chronic myeloid leukemia (CML), and according to IQVIA National Sales Perspectives data, the branded drug recorded approximately $253.8 million in US sales for the 12 months ended April 2026.
Dr Reddy’s North America CEO framed the launch as part of a broader oncology push, with the company stating it remains focused on strengthening its oncology portfolio and partnering across the healthcare system to keep critical treatments accessible and affordable.
Why It Matters for the Stock
A 180-day exclusivity window on a drug with a quarter-billion-dollar US market gives Dr. Reddy’s a meaningful, if temporary, revenue runway in its complex generics pipeline, a category where margins tend to be richer than standard generics.
The launch comes at a time when the company’s North America generics business has faced pressure, with Q4 profit having dropped sharply in recent quarters, making high-value launches like this one a closely watched offset.
Adani Green Energy: World’s Largest BESS Milestone at Khavda
Adani Green Energy has commissioned a cumulative 3.37 GWh Battery Energy Storage System at Khavda, Gujarat, the world’s largest single-location BESS deployment outside China, achieved within ten months of construction. The commissioning includes the 1.37 GWh added in March 2026, taking the site’s total operational storage to 3.37 GWh.
To put the scale in context, the system can store enough clean energy to power nearly one million homes for a full day, comparable to peak demand across cities like Indore or Chandigarh or the entire state of Goa.
The company isn’t stopping here. AGEL has said it targets adding over 10 GWh of battery storage capacity in FY27 and 50 GWh over the next five years, with an investment of around ₹15,000 crore earmarked for the FY27 expansion alone.
The Khavda complex itself is a 30 GW hybrid solar-wind project being developed across 538 sq km, on track to become the world’s largest power plant of any kind by 2029.
Check Live: ADANI GREEN ENERGY Share Price Chart: Live
Stock Impact Snapshot
| Development | Detail |
|---|---|
| BESS Capacity Commissioned | 3.37 GWh cumulative at Khavda |
| Global Ranking | Largest single-location BESS outside China |
| Construction Time | ~10 months |
| FY27 Storage Target | 10+ GWh |
| 5-Year Storage Target | 50 GWh |
| FY27 Capex for BESS | ~₹15,000 crore |
Energy storage capacity is the missing link that converts intermittent renewable generation into dispatchable, round-the-clock power, a theme NiftyTrader has flagged as central to the re-rating narrative for renewable energy stocks.
Check Live: INDIAN RENEWABLE ENERGY DEVELOPMENT AGENCY Free LTP Calculator For Option Chain
JSW Energy: ₹1,410 Crore Bet on Chhattisgarh Thermal Asset
JSW Energy has signed a definitive agreement to acquire 100% equity shares of Maruti Clean Coal & Power Limited (MCCPL), which operates a 300 MW thermal power project in Korba, Chhattisgarh, at an enterprise value of approximately ₹1,410 crore. The sellers are Kolahai Infotech Private Limited and SFI Parcel Services Private Limited.
The asset comes with locked-in revenue visibility: the plant has a long-term Power Purchase Agreement of 195 MW (net) with Rajasthan discoms, routed through PTC India, with a residual PPA life of around 14 years.
An additional 5 percent of power goes to the Chhattisgarh discom at variable cost, while the remaining roughly 64 MW is sold in the merchant market. Fuel security is also addressed, with coal supply secured through a long-term agreement with SECL and linkage under the SHAKTI scheme.
JSW Energy’s joint MD and CEO described the move as disciplined portfolio-building, noting the acquisition reflects the company’s “Build vs. Buy” approach, targeting calibrated, value-accretive inorganic opportunities, with MCCPL being earnings-accretive from day one.
Post-completion, the company’s total installed and locked-in thermal capacity will rise to 5,958 MW and 10,958 MW respectively. The deal carries a Long Stop Date of July 31, 2026, subject to regulatory approvals.
Deal Snapshot: JSW Energy–MCCPL
| Parameter | Detail |
|---|---|
| Target | Maruti Clean Coal & Power Ltd (MCCPL) |
| Stake Acquired | 100% |
| Enterprise Value | ~₹1,410 crore |
| Asset | 300 MW thermal plant, Korba, Chhattisgarh |
| Long-term PPA | 195 MW (net) with Rajasthan discoms via PTC India |
| Residual PPA Life | ~14 years |
| Post-Deal Thermal Capacity (Installed/Locked-in) | 5,958 MW / 10,958 MW |
| Expected Closing | By July 31, 2026 |
KIMS: Promoters to Pump in ₹600 Crore via Warrants
The board of Krishna Institute of Medical Sciences (KIMS) approved a preferential allotment of 77.02 lakh warrants priced at ₹779 each to promoters and promoter group entities, aiming to raise about ₹600 crore.
Each warrant can be converted into one equity share of face value ₹2 within 18 months of allotment, with allottees paying 25 percent upfront and the balance 75 percent at conversion. The primary allottees include Dr. Abhinay Bollineni, Adwik Bollineni, and promoter entity Bharas Ventures LLP.
The capital raise dovetails with KIMS’ expansion plans. Analyst commentary ahead of the board meeting noted KIMS is looking to add over 1,300 beds, roughly 25 percent of its existing capacity, over the next 3-4 years, with management indicating this represents peak debt levels for the company, suggesting the fundraise is aimed at strengthening the balance sheet and trimming interest costs.
A promoter-funded warrant issue at a defined price is often read by the market as a confidence signal, since promoters commit capital upfront rather than diluting through public routes.
Nestlé India: Maggi Infestation Claims Rejected After FSSAI Notice
Nestlé India found itself in the spotlight after social media allegations of insect infestation in a Maggi noodles packet prompted regulatory attention.
The Food Safety and Standards Authority of India (FSSAI) took formal cognisance of the complaints and issued a notice to the company, seeking a detailed Action Taken Report covering batch-wise quality testing records, supplier details, and corrective measures.
In its response, Nestlé India was unambiguous. The company said in a filing that it “categorically rejects allegations circulating on media based on an unverified account regarding the presence of infestation, allegedly on MAGGI noodles,” adding that laboratory tests on batch and market samples confirmed the products met all quality and food safety standards.
The company further said the account holder making the claim did not respond to multiple requests to provide the specific sample for scientific verification, and per the filing, it was “yet to receive” any sample from the complainant, who remained unreachable on social media.
The episode wasn’t without market consequence. Nestlé India shares opened at Rs 1,431.10 and closed at Rs 1,375.70 on Friday, down 3.29 percent from the previous close, as the controversy weighed on investor sentiment even as the company pushed back on the claims.
Quick Reference: Nestlé–Maggi Episode Timeline
| Event | Detail |
|---|---|
| Trigger | Social media claims of infestation in Maggi packet |
| Regulatory Action | FSSAI issued notice, sought Action Taken Report |
| Company Response | Categorically rejected claims; cited clean lab test results |
| Sample Status | Complainant did not provide sample for verification |
| Stock Reaction (June 12) | Closed at ₹1,375.70, down 3.29% |
Other Names in Focus
Beyond the headline movers, a few additional developments are worth tracking.
LIC’s CEO and MD R Doraiswamy reiterated that despite rising competition in the life insurance sector, the Corporation will stay focused on strengthening its leadership position while contributing to national development as it approaches its platinum jubilee.
Separately, NLC India announced it has been declared the preferred bidder for a critical and strategic mineral block auction conducted by the Ministry of Mines in Telangana.
Bottom Line
Friday’s sharp rebound has put the Nifty back in a constructive zone above 23,500, but the day’s real action lies in the stock-specific triggers.
Dr Reddy’s gets a high-value, exclusivity-backed US launch in a tough generics environment; Adani Green cements its lead in grid-scale storage with clear multi-year expansion targets; JSW Energy adds an earnings-accretive thermal asset at a reasonable valuation; KIMS’ promoter-backed warrant issue signals confidence ahead of a major bed-capacity expansion; and Nestlé India navigates a reputational episode that has already dented the stock, even as the company stands firmly behind its quality testing.
As always, regulatory approvals (JSW Energy, KIMS) and FSSAI’s final findings (Nestlé) remain the key follow-through items to watch.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult a SEBI-registered financial advisor before making any investment decisions. Data as of June 13, 2026 (market data) and June 12, 2026 closing prices.
